FDA Inspection 1084076 — Roswell Park Cancer Institute Corporation. Div. of Pathology

Roswell Park Cancer Institute Corporation. Div. of Pathology — FEI 1372120

The FDA completed an inspection of Roswell Park Cancer Institute Corporation. Div. of Pathology on March 1, 2019 in Buffalo, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
March 1, 2019
Fiscal Year
2019
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Buffalo, NY (United States)